Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06216041 Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06216041
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part voluntarily and are able to sign a consent form after fully understanding what the trial involves
  • You are between 18 and 45 years old (inclusive)
  • If you are male, you weigh at least 50 kg (about 110 lbs); if you are female, you weigh at least 45 kg (about 99 lbs)
  • Your Body Mass Index (BMI) is between 18 and 28 kg/m²
  • You are willing and able to use effective birth control (such as abstinence, condoms, an IUD, or a combination of barrier methods) from the start of screening until 6 months after your last dose of the trial drug
  • Your vital signs (such as blood pressure and heart rate) and physical exam results are normal or only slightly abnormal in a way that is not medically concerning

Who may not be able to join:

  • You have a history of drug allergies, specific allergic conditions (such as asthma or hives), or a known or suspected allergy to the trial drug or its ingredients
  • You have taken any prescription medicines, over-the-counter medicines, herbal remedies, or health supplements in the 2 weeks before screening
  • Your lab tests, ultrasound, chest X-ray, or other medical checks show results that are considered clinically significant concerns, or you have had a significant medical condition in the past 6 months (including but not limited to conditions affecting the gut, kidneys, liver, nerves, blood, hormones, lungs, immune system, mental health, or heart and blood vessels)
  • You ate certain foods that can affect how the body processes medicines (such as grapefruit, dragon fruit, or mango) within 7 days before screening, or did intense exercise during that time
  • You or a close blood relative (parent, sibling, or child) has a history of certain heart rhythm problems, long or short QT syndrome, unexplained sudden death before age 40, or sudden infant death syndrome
  • You have abnormal levels of certain minerals in your blood (such as potassium, magnesium, or calcium) that are considered clinically significant
  • You have a clinically significant abnormal heart tracing (ECG), or a specific heart rhythm measurement (QTcF) greater than 450ms
  • Your kidney function, as measured by a specific calculation, falls below a certain level (confirm with trial site)
  • You have or have had a chronic or active digestive condition, such as stomach ulcers, esophageal disease, intestinal inflammation, active gastrointestinal bleeding, or relevant gastrointestinal surgery
  • You had a major surgery (not including diagnostic procedures) in the 6 months before screening, are planning surgery during the study, or had surgery that may affect how your body handles medicines
  • You took part in another clinical trial within the 3 months before screening and actually received the trial drug in that study
  • You donated blood or lost a significant amount of blood (more than 450 ml) in the 3 months before screening
  • You have a history of heavy alcohol use (averaging more than 14 units per week in the past 3 months), are unable to avoid alcohol during the trial, or test positive on a breath alcohol test
  • You smoked more than 5 cigarettes per day on average in the 3 months before screening
  • You have a history of drug or substance abuse, or test positive on a urine drug screening
  • You have specific dietary requirements that would prevent you from following the trial's standard meal plan
  • You have difficulty swallowing
  • You are currently breastfeeding or have a positive pregnancy test result
  • You became acutely unwell or started taking new medication between your screening visit and the time you would take the first trial drug dose
  • You consumed chocolate, caffeine, or foods or drinks rich in xanthines in the 24 hours before taking the first trial drug dose
  • You consumed any alcohol-containing product or tested positive on a breath alcohol test in the 24 hours before taking the trial drug
  • The trial doctor believes, for any other reason, that you are not suitable to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hong Zhang, The First Hospital of Jilin University

Phone: 18943642700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
1 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse Events following oral doses (single, multiple and food effect)of IMM-H014 and placebo; Number of participants with abnormal laboratory tests results and abnormal physical exam findings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov